Testing should not be done in all patients treated with clopidogrel who are undergoing percutaneous coronary intervention.
Population Health Research Institute, Hamilton General Hospital, 237 Barton St East, Hamilton, Ontario, Canada. pareg@McMaster.ca
Guillaume
G
Paré
John W
JW
Eikelboom
Dirk
D
Sibbing
Isabell
I
Bernlochner
Adnan
A
Kastrati
D001189:Aryl Hydrocarbon Hydroxylases / Q000378:metabolism*; D054316:Biomarkers, Pharmacological / Q000378:metabolism*; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D005820:Genetic Testing; D006801:Humans; D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine / Q000031:analogs & derivatives*
D054316:Biomarkers, Pharmacological; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine